Material and methods
We collected epidemiologic, clinical, staging and survival data for 357 patients with a diagnosis of AIDS-KS enrolling for HIV-care at the Jos University Teaching Hospital. Patients were staged according to the AIDS Clinical Trials Group (ACTG) criteria, which are based on the evaluation of tumor extension (T), CD4+ cell count (I), and patient's systemic status (S), stratified by good (0) versus poor (1) risk. Information on survival was obtained through an active follow-up on verification of vital status of the patients. Survival analysis was computed by the KaplanMeier method, and the log-rank test was used to test the difference between subgroups.
Results
During the period of the study (2004) (2005) (2006) (2007) (2008) , there were 197 women (55.2%) and 160 (44.8%) men with AIDSrelated Kaposi Sarcoma. Their mean age was 37±8 years and the median follow-up was 15 months (1-49 months). The median CD4+ and viral load were 107cells/mm³ and 58,561copies/ml respectively at baseline. Only 42 (11.8%)
were on HAART at KS diagnosis, however all patients were commenced on HAART in line with existing national guidelines subsequently. 262(74.4%) had poor immune system status (I1: CD4+<200cells/mm 3 ), 77.5% had widespread tumor extension (T1) and 80.2% had systemic disease (S1). Poor immune system (I1) status (AOR 2.07, CI 1.25-3.42, p=0.002) and presence of systemic disease (S1) (AOR 2.10, CI 1.03-4.28, p=0.004) were independently associated with mortality.
Regarding ACTG classification, the 4-year survival rate was 67% for I0 vs 46% for I1 (p=0.05), 58% for S0 vs 49% for S1 (p=0.41), 60% for T0 vs 46% for T1 (p=0.19).
Conclusion
Poor immune status and systemic disease are independent predictors of mortality in patients with AIDS-KS in Nigeria.
